French Government Positioned to Take Stake in Sanofi Unit Post-Private Equity Sale

2 min read | October 21, 2024 03:33 AM PDT | By Team Kalkine Media

Google News:

French Government Positioned to Take Stake in Sanofi Unit Post-Private Equity Sale — Image source: Shutterstock

Recent News

Why Moderna Is Capturing Market Attention Again?

Eli Lilly Coverage Buzz Keeps Healthcare Market Attention High

Sandisk Gains Attention As an AI-Driven Growth Stock

Why Micron Technology Is Benefiting From the AI Growth Wave?

Make Kalkine Media
My Trusted Source

Highlights

France is poised to acquire a 2% stake in Sanofi SA's consumer healthcare unit, Opella, as part of a €16 billion deal with private equity firm Clayton, Dubilier & Rice (CD&R).

The French government expressed concerns regarding foreign control and job security, leading to assurances that Opella's operations will remain in France.

The deal, which follows a competitive bidding process, is anticipated to close in mid-2025, pending regulatory approvals.

France is set to acquire a minority stake in Sanofi SA (NASDAQ:SNY) consumer healthcare unit, Opella, amid the pharmaceutical company's ongoing €16 billion agreement to sell a 50% share of the division to US private equity firm Clayton, Dubilier & Rice (CD&R). The acquisition comes as a response to rising political concerns about foreign control and its potential impact on employment within the country.

Sanofi has entered exclusive negotiations with CD&R to divest half of Opella, the division responsible for popular products such as Doliprane, a widely used painkiller in France. The Financial Times reports that French investment bank Bpifrance is poised to purchase a 2% stake in Opella, providing the French government with a degree of oversight and influence in the division's operations.

Economy Minister Antoine Armand announced that the government has secured assurances that Opella's operations will continue to be based in France. This move aims to address worries from the public and various stakeholders regarding job security and the implications of foreign ownership.

Despite receiving a late bid from French competitor PAI, CD&R's offer, which values Opella at €16 billion, was ultimately accepted by Sanofi. The transaction reflects a broader trend of consolidation within the healthcare sector, where private equity firms are increasingly targeting established pharmaceutical businesses.

The deal is expected to close in mid-2025, pending the necessary regulatory approvals. This strategic partnership is seen as a way for Sanofi to focus on its core operations while ensuring that Opella remains an integral part of France's healthcare landscape.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.